PRECIGEN, INC. Goodwill, Impaired, Accumulated Impairment Loss
PRECIGEN, INC. (PGEN) had Goodwill, Impaired, Accumulated Impairment Loss of $36.19 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Goodwill and Other
us-gaap:GoodwillImpairedAccumulatedImpairmentLoss · last filed 2026-08-04
- 2026-06-30: Goodwill, Impaired, Accumulated Impairment Loss $36.19M.
- 2026-03-31: Goodwill, Impaired, Accumulated Impairment Loss $36.19M.
- 2025-12-31: Goodwill, Impaired, Accumulated Impairment Loss $36.19M.
- 2025-09-30: Goodwill, Impaired, Accumulated Impairment Loss $36.19M.
| Period end | Goodwill, Impaired, Accumulated Impairment Loss | Goodwill, Impaired, Accumulated Impairment Loss as first filed |
|---|---|---|
| 2026-06-30 | $36.19M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $36.19M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $36.19M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $36.19M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $36.19M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $32.28M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $32.28M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $26.50M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $26.50M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $24.87M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $24.87M 10-K · filed 2025-03-19 | |
| 2023-09-30 | $14.48M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $14.48M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $14.48M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $14.48M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $14.48M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $14.48M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $44.13M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $14.00M 10-K · filed 2023-03-06 | $43.64M 10-K · filed 2022-03-01 |
| 2021-09-30 | $43.64M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $43.64M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $43.64M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $43.64M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $53.28M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $53.28M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $43.64M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $43.64M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $14.00M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $13.82M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $13.82M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $13.82M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $13.82M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $13.82M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $13.82M 10-Q/A · filed 2018-08-13 | |
| 2017-12-31 | $13.82M 10-Q · filed 2018-11-08 | |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $0.00 10-K · filed 2018-03-01 | |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $0.00 10-K · filed 2017-03-01 | |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $0.00 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $0.00 10-K · filed 2016-02-29 | |
| 2014-09-30 | $0.00 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $0.00 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $0.00 10-K · filed 2015-03-02 | |
| 2013-09-30 | $0.00 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $0.00 10-Q/A · filed 2013-10-21 | |
| 2012-12-31 | $0.00 10-Q · filed 2013-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |